Results 221 to 230 of about 25,462 (288)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy. [PDF]

Cureus
Yildirim U, Ozkurt S, Yalcin AU.
europepmc   +1 more source

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, Volume 59, Issue 5, May 2026.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source

NELL-1-Positive Membranous Nephropathy Following Inhalational Mercury Exposure. [PDF]

Kidney Int Rep
Tahillioglu Y, Hurdogan O, Dirim AB, Artan AS, Celik A, Cebeci E, Oto OA, Ozluk Y, Yazici H, Turkmen A, Ozturk S.   +10 more
europepmc   +1 more source

Baseline and 4‐year associations between prediabetes and kidney impairment: Insights from the ILERVAS cohort

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3777-3787, May 2026.
Abstract Aims Prediabetes is a prevalent condition associated with increased cardiovascular and renal risk. However, the long‐term impact of haemoglobin A1c (HbA1c) within the range defined as prediabetes on kidney function remains unclear. This study aimed to evaluate the association between prediabetes and renal function (estimated glomerular ...
Aitziber Izarra, Marcelino Bermúdez‐López, José M. Valdivielso, Reinald Pamplona, Gerard Torres, Dídac Mauricio, Eva Castro‐Boqué, Elvira Fernández, Rafael Simó, Cristina Hernández, Albert Lecube, on behalf of the ILERVAS project collaborators, Eva Miquel, Marta Ortega, Ferran Barbé, Jordi de Batlle, Jessica González, Manuel Portero‐Otín, Mariona Jové, Josep Franch‐Nadal, Esmeralda Castelblanco, Pere Godoy, Montse Martinez‐ Alonso, Cristina Farràs   +23 more
wiley   +1 more source

Autoantibodies reactive with glomerular endothelial cells and podocytes in patients with membranous nephropathy. [PDF]

J Transl Autoimmun
Petr V, Purohit S, Poppelaars F, Renner B, Laskowski J, Whelan R, Kulik L, Kendrick J, Frazer-Abel A, Jalal D, Marcolin B, Schmelzer I, Debiec H, Ronco P, Saleem MA, Satchell SC, Thurman JM.   +16 more
europepmc   +1 more source

Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4066-4081, May 2026.
Abstract Aims Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short‐term liraglutide on early changes in the renal microcirculation post‐induction of diabetes.
Yuan Li, Weiqi Liu, Yingyu Wang, Bing Wang, Xiang Xu, Bingwei Li, Mingming Liu, Xu Zhang, Ruijuan Xiu   +8 more
wiley   +1 more source

ST-segment elevation myocardial infarction as the first clue to membranous nephropathy: A case report. [PDF]

Medicine (Baltimore)
Wang D, Deng H, He M, He T.
europepmc   +1 more source

Whole Blood Transcriptomic Analysis of Sickle Cell Trait

European Journal of Haematology, Volume 116, Issue 5, Page 535-544, May 2026.
ABSTRACT Sickle cell trait (SCT) is the heterozygous carrier state for the HBB missense variant which causes sickle cell disease (SCD). SCT has been associated with increased risk of venous thromboembolism and chronic kidney disease as well as alterations in clinical laboratory parameters. To investigate differential gene expression in SCT, we used RNA
Mari Johnson, Yanwei Cai, Ana Gabriela Vasconcelos, Peter Orchard, Paul L. Auer, Guillaume Lettre, Jia Wen, Nora Franceschini, Charles Kooperberg, Wei Sun, Li Hsu, Laura M. Raffield, Alex P. Reiner   +12 more
wiley   +1 more source